Corticosteroids

Corticosteroids (CS) are usually the first-line treatment for sarcoidosis because they provide strong and rapid anti-inflammatory effects. They act through several pathways, including inhibition of TNF-α, IFN-γ and related NF-κB signalling.

Treatment decisions depend on the organs involved, symptoms and risk of permanent damage. Your specialist determines the dose and duration for your situation.

However, the optimal therapeutic dose and duration of treatment have not been standardised because adequately randomised controlled clinical trials are lacking. When used in the short term, CS can dramatically improve disease-related symptoms, normalise molecular biomarkers, and restore lung function and radiographic findings.

Long-term benefits and risks must be reviewed regularly. Corticosteroids can improve symptoms and lung function, but prolonged use may cause important side effects. If disease remains active or steroid-sparing treatment is needed, specialists may consider medicines such as methotrexate or biologic therapy.

Never change, stop or add treatment without medical advice.

However, their long-term effects and benefits are unclear, as they often fail to slow disease progression or prevent fibrosis, and there is no evidence that they improve survival.

Their side effects contribute to lower perceived quality of life among patients treated with CS compared with untreated patients who have similar disease manifestations. Despite this adverse-effect profile, CS are the most commonly used first-line therapy, especially in acute life-threatening or symptomatic disease.

Rating: 0 stars, 0 votes.